How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment, with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development ...

Liraglutide is a GLP-1 analog, which is resistant to degradation. Phase III trials have demonstrated that liraglutide effectively controls glucose levels, while reducing bodyweight.

Moving Biotech gets Health Canada approval to initiate phase 2a INFLAM MOTION clinical trial for knee osteoarthritis: Lille & Paris, France Saturday, March 29, 2025, 17:00 Hrs [I ...